Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

ramucirumab (IMC-1121B); docetaxel

A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer

Номер протокола13892
ФазаФаза III
Участников по плану — во всех странах исследования1 144
Сроки06.08.2008 — 19.11.2020
Начало: 6 августа 2008Окончание: 19 ноября 2020
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00703326/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 1144 чел. во всех странах исследования.
  • Плановая дата окончания (11.2020) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолТолько женщины
Здоровые добровольцынет

Главное из критериев

  • Состояние пациента (ECOG)0–1
  • Биомаркеры в критерияхHER2
  • Опухольнужен измеримый очаг (RECIST)
  • Стадияметастатическая (IV)

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 21 · невключение: 14

Критерии включения

  • Participant is able to provide signed informed consent
  • Participant is female and ≥ 18 years of age or older if required by local laws or regulations
  • Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis
  • Participant has measurable and/or non-measurable disease
  • Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)
  • Participant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer
  • Participant completed (neo) adjuvant taxane therapy at least 6 months prior to randomization
  • Participant completed (neo) adjuvant biologic therapy at least 6 weeks prior to randomization
  • Participant completed all prior radiotherapy with curative intent ≥ 3 weeks prior to randomization
  • Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting ≥ 2 weeks prior to randomization
  • Participant's left ventricular ejection fraction is within normal institutional ranges
  • Participant has resolution to grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to grade ≤ 2
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Participant is amenable to compliance with protocol schedules and testing
  • Participant has adequate hematological functions \[absolute neutrophil count (ANC) ≥ 1500 cells/microliter (mcL), hemoglobin ≥ 9 grams/deciliter (g/dL), and platelets ≥ 100,000 cells/mcL and ≤ 850,000 cells/mcL\]
  • Participant has adequate hepatic function \[bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times the upper limit of normal (ULN), or ≤ 5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase ≤ 5.0 times the ULN\]
  • Participant has serum creatinine ≤ 1.5 x ULN. If serum creatinine > 1.5 x ULN the calculated creatinine clearance should be > 40 milliliters/minute (mL/min)
  • Participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA); if urine protein ≥ 2+, a 24-hour urine collection must demonstrate < 1000 milligrams (mg) of protein in 24 hours to allow participation in the study
  • Participant must have adequate coagulation function as defined by international normalized ratio (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding (defined as within 14 days of randomization) or pathological condition that carries a high risk of bleeding (such as, tumor involving major vessels or known varices)
  • Women of childbearing potential must implement adequate contraception in the opinion of the investigator
  • Participant has not received prior biologic therapy for metastatic or locally recurrent and inoperable breast cancer

Критерии невключения

  • Participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that she has been disease free for > 3 years
  • Participant has a known sensitivity to docetaxel or other drugs formulated with polysorbate 80
  • Participant has a known sensitivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF)
  • Participant has a history of chronic diarrheal disease within 6 months prior to randomization
  • Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomization
  • Participant has participated in clinical trials of experimental agents within 4 weeks prior to randomization
  • Participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
  • Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within 14 days prior to randomization
  • Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
  • Participant has uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator
  • Participant has brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease
  • Participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
  • Participant has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
  • Participant is pregnant or lactating

Источник: ClinicalTrials.gov, NCT00703326 · запись обновлена в реестре 6 декабря 2021.

Дизайн и результаты

ДизайнРандомизированное, двойное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)1 144
Что измеряют — первичные конечные точки (1), вторичных — 8
  • Progression-Free Survival (PFS) — Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 56 months)

Цель исследования

The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00703326 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.